Skip to content

Protagonist Therapeutics PTGX Short- term Investments

Short- term Investments at other companies

Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
United Therapeutics logo
United TherapeuticsUTHR
PTC Therapeutics logo
PTC TherapeuticsPTCT
Johnson & Johnson logo
Johnson & JohnsonJNJ

Other financials

Income statement

See full
Revenue$56.4M+99.0%
Operating income-$3.6M+81.1%
Net income$3.8M+132%
EPS (diluted)$0.05+126%

Balance sheet

See full
Cash & equivalents$193.7M+38.7%
Total debt$9.8M-13.9%
Total equity$655.5M-4.9%
Total assets$697.5M-6.0%

Cash flow

See full
Operating cash flow-$48.9M-139%
CapEx$215.0K-60.6%
Free cash flow-$49.2M-139%

Valuation

See full
Market cap$7.26B+127%
Enterprise value$7.07B+130%
P/S98×+82.6×

Profitability

See full
Operating margin-192.4%-205pp
Net margin-154.9%-182pp
FCF margin-12,264.3%-12,527pp

Returns & leverage

See full
Return on equity-17.1%-26.1pp
Debt / equity0.0×
Current ratio17.8×+0.5×

Where this comes from

Reported directly by Protagonist Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:MarketableSecuritiesCurrent.

The official record: Protagonist Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Protagonist Therapeutics's short- term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Protagonist Therapeutics's short- term investments?
Protagonist Therapeutics (PTGX) reported short- term investments of $354.07M in Q1 2026.
How has Protagonist Therapeutics's short- term investments changed year-over-year?
Protagonist Therapeutics's short- term investments decreased by 18.5% year-over-year, from $434.71M to $354.07M.
What is the long-term trend for Protagonist Therapeutics's short- term investments?
Over 5 years (2020 to 2025), Protagonist Therapeutics's short- term investments has grown at a 18.4% compound annual growth rate (CAGR), from $188.45M to $438.97M.